Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


New Animal Pharm report gives latest insight into ASF situation

Animal Pharm's latest one-off report provides an up-to-date overview of the global African swine fever (ASF) trajectory.   

ASF is currently the most important threat to the pig industry worldwide. At present, there is no effective vaccine or treatment for ASF. Control is based on containing outbreaks through biosecurity measures and the stamping out of infected and in-contact animals. One of the main challenges for the current outbreaks in Europe and Asia is the transmission of the virus by wild boar.

Animal Pharm teamed up with Scotland-based animal health consultancy Ingentium to produce the report, which explores the likely development of treatments.

A prompt diagnosis is critical to restrain and control ASF. The diagnostics review section of the report provides a summary of virus detection tests and antibody detection tests. The report also provides market estimates for a potential ASF vaccine and looks at patenting activity in this space.

Contents pages, an executive summary and sample pages can be accessed here. For more information or to purchase the full report please contact us.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts